VG H&N course intro Florence 2016.pptx

2066-2067 / 2351

Recurrent and/or metastatic non-curative disease
• Anti-EGFR first-line palliative
treatment: mAbs
• Anti-EGFR second line: mAbs and TKIs
03/01/13